| New important advice to minimise the risk of serious hepatotoxicity, interstitial lung disease and cardiac failure |
| Celgene Pte Ltd, Singapore, would like to inform healthcare professionals of important new safety information regarding Pomalyst (pomalidomide). A European review concluded that pomalidomide can cause serious hepatotoxicity (acute hepatitis), interstitial lung disease and cardiac failure. The safety review was based on data from clinical trials, reports from clinical practice as well as published case reports. The Singapore's Package Insert and Patient Information Leaflet for Pomalyst will be updated to include the above-mentioned newly identified risks. Please refer to the following website in HSA for details: http://www.hsa.gov.sg/content/hsa/../pomalyst-pomalidomidenewimportantadvicetominimisetheriskofseriou.html In Hong Kong, the above product is not a registered pharmaceutical product. Related news has been released by the MHRA, and was posted on the Drug Office website on 21 May 2015. Ends/ Friday, July 03, 2015 Issued at HKT 14:00 |
| 欢迎光临 药群论坛 (http://www.yaoqun.net/) | Powered by Discuz! X3.2 |